AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition.
As set forth in Exhibit 99.1 of this Current Report on Form 8-K, AmpliPhi Biosciences Corporation had approximately $5.7 million of cash and cash equivalents at December 31, 2016.
Item 7.01 Regulation FD Disclosure.
Attached hereto as Exhibit 99.1 is a copy of a presentation that we intend to utilize in connection with various meetings with securities analysts, investors and others at the Annual J.P. Morgan Healthcare Conference, commencing on January 9, 2017. Exhibit 99.1 is incorporated herein by reference.
This Current Report on Form 8-K and the information in this Item 7.01 is being “furnished” and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor will it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
About AmpliPhi Biosciences Corporation (NYSEMKT:APHB)
AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Company is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile). Its product candidates include AB-SA01, AB-PA01 and AB-CD01. AmpliPhi Biosciences Corporation (NYSEMKT:APHB) Recent Trading Information
AmpliPhi Biosciences Corporation (NYSEMKT:APHB) closed its last trading session up +0.017 at 0.502 with shares trading hands.